VMI
VYNE icon

VHCP Management II’s VYNE Therapeutics VYNE Stock Holding History

VHCP Management II’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,722
Closed -$12.8M – 22
2018
Q1 		$12.8M Buy
+4,722
New +$11.5M 3.08% 11

Other funds holding VYNE

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

VHCP Management II's VYNE Position: Q2 2018 in Review

VHCP Management II sold out of VYNE Therapeutics (VYNE) in Q2 2018, closing a stake of 4,722 shares — an estimated $12.8M sold.

VHCP Management II first reported a position in VYNE in Q1 2018 and held it in 1 quarter. The position peaked at $12.8M in Q1 2018. 48 funds tracked by Wall St. Rank hold VYNE as of Q2 2018.

  • VHCP Management II reported no remaining VYNE Therapeutics position as of Q2 2018 after selling out during the quarter.
  • VHCP Management II sold 4,722 VYNE Therapeutics shares in Q2 2018, an estimated $12.8M.
  • VHCP Management II first reported a position in VYNE Therapeutics in Q1 2018 and held it in 1 quarter.
  • VHCP Management II's VYNE Therapeutics position peaked at $12.8M in Q1 2018.
  • 48 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2018.

Based on VHCP Management II's 13F filing for Q2 2018, filed 13 Aug 2018.